查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1534411

急性細菌性皮膚和結構性感染疾病的全球市場：市場規模、佔有率、趨勢分析、機會、預測，2019-2030

Acute Bacterial Skin and Skin Structure Infections Market - Global Size, Share, Trend Analysis, Opportunity and Forecast, 2019-2030, Segmented By Type of Infection; By Route of Administration; By Distribution Channel; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到2030年，全球急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場規模將達到235億美元，以2.4倍的複合年成長率快速擴張。

由於ABSSSI盛行率不斷增加、抗生素抗藥性、治療方案的進步、醫療保健成本的上升和宣導活動等，全球急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場正在以顯著的速度蓬勃發展。 Masu。

該報告估計2023年全球急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場以金額為準為96.5億美元。 BlueWeave 預測，在 2024 年至 2030 年的預測期內，全球急性細菌性皮膚和皮膚結構感染疾病(ABSSSI) 市場規模將以 10.55% 的複合年成長率成長，到 2030 年將達到 234.9 億美元。由於製藥和生物製藥公司的意識增強和研發活動的增加，全球急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場正在顯著成長。引起這些感染疾病的常見細菌包括化膿性鏈球菌和金黃色葡萄球菌，抗 MRSA 藥物是一個重要的新興概念。管道開拓、研發支出和藥物核准預計將推動市場。 Melinta Therapeutics 等主要市場參與者也推出了醣肽抗生素 KIMYRSA 等新產品和活動。預計這些因素將在預測期內推動市場。

機會－診斷和治療的技術進步

診斷工具和治療方法的最新技術創新正在改變全球急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場的格局。先進的影像技術和快速診斷測試正在增強早期檢測，從而實現及時干預並改善患者的治療結果。此外，新抗生素的開發和抗生素抗藥性菌株的治療方法正在解決以前未滿足的醫療需求。這些技術進步不僅減少了住院時間和醫療費用，也擴大了全球市場範圍。因此，由於醫療技術的不斷進步，ABSSSI 的全球市場有望大幅成長。

地緣政治緊張局勢加劇對全球急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場的影響

不斷升級的地緣政治緊張局勢正在對全球急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場造成嚴重破壞。供應鏈的中斷，特別是抗生素和醫療用品的供應鏈中斷，會影響病患照護和治療效果。政治不穩定和經濟制裁也會擾亂藥品的生產和分配，導致藥品短缺和成本增加。國際合作下降和外交關係緊張可能會阻礙研發工作。

急性細菌性皮膚和皮膚結構感染疾病的全球市場 (ABSSSI)

全球急性細菌性皮膚和皮膚結構感染疾病(ABSSSI) 市場 – 按分銷管道

按分銷管道分類，全球急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場分為醫院藥房、零售藥房和線上藥房部分。醫院藥房部門因其有效管理複雜感染疾病、及時提供所需藥物以及提供先進醫療基礎設施的能力而受到認可，特別是在需要即時和重症監護的醫院環境中，我們在全球ABSSSI 市場中佔據主導地位。

競爭格局

全球急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場競爭激烈。該市場的主要企業包括輝瑞、默克、艾伯維、羅氏、葛蘭素史克、強生、禮來公司、諾華、賽諾菲、阿斯特捷利康、梯瓦製藥工業有限公司和邁蘭NV。這些公司正在增加對感染疾病活動、併購、合資、聯盟、授權合約的投資，我們正在使用各種策略，包括發布新產品和新劑量。

該報告的詳細分析提供了有關全球急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場的成長潛力、未來趨勢和統計數據的資訊。我們也研究了推動市場總規模預測的因素。該報告致力於提供全球急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場的最新技術趨勢以及行業見解，以幫助決策者做出明智的策略決策。此外，我們也分析了市場的成長動力、挑戰和競爭力。

目錄

第1章 研究框架

第 2 章執行摘要

第3章全球急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場分析

  • 產業價值鏈分析
  • DROC分析
    • 生長促進因子
      • 抗生素抗藥性的蔓延
      • 高齡化社會
      • 侵入性醫療程序的增加
      • 提高對 ABSSSI 的認知
    • 抑制因素
      • 治療費用上漲
      • 有效抗生素的供應有限
    • 機會
      • 診斷和治療技術進步
      • 專注新興市場
    • 任務
      • 抗生素的不當使​​用和自我藥療
      • 缺乏衛生意識和習慣
  • 科技進步/最新趨勢
  • 法律規範
  • 波特五力分析

第4章全球急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場：行銷策略

第5章全球急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場：區域分析

  • 急性細菌性皮膚和皮膚結構感染疾病(ABSSSI) 全球市場，區域分析，2023 年
  • 全球急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場，市場吸引力分析，2024-2030

第6章急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）的全球市場概述

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按感染類型
      • 院內ABSSI
      • 社區獲得性 ABSSI
    • 依給藥途徑
      • 口服
      • 胃腸外的
      • 話題
    • 按分銷管道
      • 醫院藥房
      • 零售藥房
      • 網路藥房
    • 按地區
      • 北美洲
      • 歐洲
      • 亞太地區
      • 拉丁美洲
      • 中東/非洲

第7章北美急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場

第8章歐洲急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場

第9章亞太地區急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場

第10章拉丁美洲急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場

第11章中東和非洲急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場

第12章競爭格局

  • 主要參與者及其產品列表
  • 急性細菌性皮膚和皮膚結構感染疾病(ABSSSI) 全球公司市場佔有率分析，2023 年
  • 透過管理參數進行競爭基準化分析
  • 重大策略發展（合併、收購、聯盟等）

第13章地緣政治緊張局勢加劇對全球急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）市場的影響

第14章 公司簡介

  • Pfizer
  • Merck &Co.
  • AbbVie
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline
  • Johnson &Johnson
  • Eli Lilly and Company
  • Novartis AG
  • Sanofi SA
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd
  • Mylan NV
  • 其他主要企業

第15章 主要戰略建議

第16章調查方法

簡介目錄
Product Code: BWC24485

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Size Zooming 2.4X at Stellar CAGR to Touch USD 23.5 Billion by 2030

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is flourishing at a significant growth rate due to increasing ABSSSI incidence rates, antibiotic resistance, advancements in treatment options, and rising healthcare expenditure and awareness initiatives.

BlueWeave Consulting, a leading strategic consulting, and Market research firm, in its recent study, estimated Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market size by value at USD 9.65 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market size to expand at a CAGR of 10.55% reaching a value of USD 23.49 billion in 2030. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is growing at a significant rate due to increasing awareness and R&D activities by pharmaceutical and biopharmaceutical companies. Common bacteria causing these infections include Streptococcus pyogenes and Staphylococcus aureus, with anti-MRSA drugs being a crucial emerging concept. Pipeline development, R&D expenditure, and drug approvals are expected to drive the market. Key market players, such as Melinta Therapeutics, are also launching new products and activities, such as KIMYRSA, a lipoglycopeptide antibiotic. These factors are expected to drive the market during the forecast period.

Opportunity - Technological advancements in diagnostics and treatment

Recent innovations in diagnostic tools and treatment modalities are revolutionizing the landscape of Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market. Advanced imaging techniques and rapid diagnostic tests are enhancing early detection, leading to prompt interventions and improved patient outcomes. Moreover, the development of novel antibiotics and therapies tailored to antibiotic-resistant strains is addressing previously unmet medical needs. These technological strides are not only reducing hospital stays and healthcare costs but also expanding the market scope globally. As a result, Global ABSSSI Market is poised for substantial growth driven by continuous advancements in medical technology.

Impact of Escalating Geopolitical Tensions on Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

Intensifying geopolitical tensions are causing significant disruptions in Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market. Disruptions in supply chains, particularly for antibiotics and medical supplies, hinder patient care and treatment efficacy. Political instability and economic sanctions can also hinder pharmaceutical manufacturing and distribution, leading to drug shortages and increased costs. Reduced international collaboration and strained diplomatic relations can stifle research and development efforts.

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market - By Distribution Channel

Based on distribution channel, Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies segments. The hospital pharmacies segment dominates the Global ABSSSI Market due to their ability to manage complex infections effectively, provide timely access to necessary medications, and offer advanced healthcare infrastructure, particularly in hospital settings where immediate and intensive care is required.

Competitive Landscape

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is fiercely competitive. Major companies in the market include Pfizer, Merck & Co., AbbVie, F. Hoffmann-La Roche Ltd, GlaxoSmithKline, Johnson & Johnson, Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd, and Mylan N.V. These companies use various strategies, including increasing investments in their R&D activities, mergers and acquisitions, joint ventures, collaborations, licensing agreements, and new product and dose releases to further strengthen their position in Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Rising Prevalence of Antibiotic Resistance
      • 3.2.1.2. Aging Population
      • 3.2.1.3. Increase in Invasive Medical Procedures
      • 3.2.1.4. Growing Awareness of ABSSSI
    • 3.2.2. Restraints
      • 3.2.2.1. High Cost of Treatment
      • 3.2.2.2. Limited Availability of Effective Antibiotics
    • 3.2.3. Opportunities
      • 3.2.3.1. Technological Advancements in Diagnostics and Treatment
      • 3.2.3.2. Focus on Emerging Markets
    • 3.2.4. Challenges
      • 3.2.4.1. Improper Antibiotic Use and Self-Medication
      • 3.2.4.2. Lack of Awareness and Hygiene Practices
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market: Marketing Strategies

5. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market: Geographical Analysis

  • 5.1. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, Geographical Analysis, 2023
  • 5.2. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, Market Attractiveness Analysis, 2024-2030

6. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Overview

  • 6.1. Market Size & Forecast, 2019-2030
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type of Infection
      • 6.2.1.1. Hospital-acquired ABSSI
      • 6.2.1.2. Community-acquired ABSSI
    • 6.2.2. By Route of Administration
      • 6.2.2.1. Oral
      • 6.2.2.2. ParentaL
      • 6.2.2.3. Topical
    • 6.2.3. By Distribution Channel
      • 6.2.3.1. Hospital Pharmacies
      • 6.2.3.2. Retail Pharmacies
      • 6.2.3.3. Online Pharmacies
    • 6.2.4. By Region
      • 6.2.4.1. North America
      • 6.2.4.2. Europe
      • 6.2.4.3. Asia Pacific (APAC)
      • 6.2.4.4. Latin America (LATAM)
      • 6.2.4.5. Middle East and Africa (MEA)

7. North America Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

  • 7.1. Market Size & Forecast, 2019-2030
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type of Infection
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
      • 7.2.4.1. United States
      • 7.2.4.1.1. By Type of Infection
      • 7.2.4.1.2. By Route of Administration
      • 7.2.4.1.3. By Distribution Channel
      • 7.2.4.2. Canada
      • 7.2.4.2.1. By Type of Infection
      • 7.2.4.2.2. By Route of Administration
      • 7.2.4.2.3. By Distribution Channel

8. Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

  • 8.1. Market Size & Forecast, 2019-2030
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type of Infection
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. Germany
      • 8.2.4.1.1. By Type of Infection
      • 8.2.4.1.2. By Route of Administration
      • 8.2.4.1.3. By Distribution Channel
      • 8.2.4.2. United Kingdom
      • 8.2.4.2.1. By Type of Infection
      • 8.2.4.2.2. By Route of Administration
      • 8.2.4.2.3. By Distribution Channel
      • 8.2.4.3. Italy
      • 8.2.4.3.1. By Type of Infection
      • 8.2.4.3.2. By Route of Administration
      • 8.2.4.3.3. By Distribution Channel
      • 8.2.4.4. France
      • 8.2.4.4.1. By Type of Infection
      • 8.2.4.4.2. By Route of Administration
      • 8.2.4.4.3. By Distribution Channel
      • 8.2.4.5. Spain
      • 8.2.4.5.1. By Type of Infection
      • 8.2.4.5.2. By Route of Administration
      • 8.2.4.5.3. By Distribution Channel
      • 8.2.4.6. Belgium
      • 8.2.4.6.1. By Type of Infection
      • 8.2.4.6.2. By Route of Administration
      • 8.2.4.6.3. By Distribution Channel
      • 8.2.4.7. Russia
      • 8.2.4.7.1. By Type of Infection
      • 8.2.4.7.2. By Route of Administration
      • 8.2.4.7.3. By Distribution Channel
      • 8.2.4.8. The Netherlands
      • 8.2.4.8.1. By Type of Infection
      • 8.2.4.8.2. By Route of Administration
      • 8.2.4.8.3. By Distribution Channel
      • 8.2.4.9. Rest of Europe
      • 8.2.4.9.1. By Type of Infection
      • 8.2.4.9.2. By Route of Administration
      • 8.2.4.9.3. By Distribution Channel

9. Asia Pacific Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

  • 9.1. Market Size & Forecast, 2019-2030
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type of Infection
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
      • 9.2.4.1. China
      • 9.2.4.1.1. By Type of Infection
      • 9.2.4.1.2. By Route of Administration
      • 9.2.4.1.3. By Distribution Channel
      • 9.2.4.2. India
      • 9.2.4.2.1. By Type of Infection
      • 9.2.4.2.2. By Route of Administration
      • 9.2.4.2.3. By Distribution Channel
      • 9.2.4.3. Japan
      • 9.2.4.3.1. By Type of Infection
      • 9.2.4.3.2. By Route of Administration
      • 9.2.4.3.3. By Distribution Channel
      • 9.2.4.4. South Korea
      • 9.2.4.4.1. By Type of Infection
      • 9.2.4.4.2. By Route of Administration
      • 9.2.4.4.3. By Distribution Channel
      • 9.2.4.5. Australia & New Zealand
      • 9.2.4.5.1. By Type of Infection
      • 9.2.4.5.2. By Route of Administration
      • 9.2.4.5.3. By Distribution Channel
      • 9.2.4.6. Indonesia
      • 9.2.4.6.1. By Type of Infection
      • 9.2.4.6.2. By Route of Administration
      • 9.2.4.6.3. By Distribution Channel
      • 9.2.4.7. Malaysia
      • 9.2.4.7.1. By Type of Infection
      • 9.2.4.7.2. By Route of Administration
      • 9.2.4.7.3. By Distribution Channel
      • 9.2.4.8. Singapore
      • 9.2.4.8.1. By Type of Infection
      • 9.2.4.8.2. By Route of Administration
      • 9.2.4.8.3. By Distribution Channel
      • 9.2.4.9. Vietnam
      • 9.2.4.9.1. By Type of Infection
      • 9.2.4.9.2. By Route of Administration
      • 9.2.4.9.3. By Distribution Channel
      • 9.2.4.10. Rest of APAC
      • 9.2.4.10.1. By Type of Infection
      • 9.2.4.10.2. By Route of Administration
      • 9.2.4.10.3. By Distribution Channel

10. Latin America Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

  • 10.1. Market Size & Forecast, 2019-2030
    • 10.1.1. By Value (USD Million)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type of Infection
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
      • 10.2.4.1. Brazil
      • 10.2.4.1.1. By Type of Infection
      • 10.2.4.1.2. By Route of Administration
      • 10.2.4.1.3. By Distribution Channel
      • 10.2.4.2. Mexico
      • 10.2.4.2.1. By Type of Infection
      • 10.2.4.2.2. By Route of Administration
      • 10.2.4.2.3. By Distribution Channel
      • 10.2.4.3. Argentina
      • 10.2.4.3.1. By Type of Infection
      • 10.2.4.3.2. By Route of Administration
      • 10.2.4.3.3. By Distribution Channel
      • 10.2.4.4. Peru
      • 10.2.4.4.1. By Type of Infection
      • 10.2.4.4.2. By Route of Administration
      • 10.2.4.4.3. By Distribution Channel
      • 10.2.4.5. Rest of LATAM
      • 10.2.4.5.1. By Type of Infection
      • 10.2.4.5.2. By Route of Administration
      • 10.2.4.5.3. By Distribution Channel

11. Middle East & Africa Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

  • 11.1. Market Size & Forecast, 2019-2030
    • 11.1.1. By Value (USD Million)
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type of Infection
    • 11.2.2. By Route of Administration
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
      • 11.2.4.1. Saudi Arabia
      • 11.2.4.1.1. By Type of Infection
      • 11.2.4.1.2. By Route of Administration
      • 11.2.4.1.3. By Distribution Channel
      • 11.2.4.2. UAE
      • 11.2.4.2.1. By Type of Infection
      • 11.2.4.2.2. By Route of Administration
      • 11.2.4.2.3. By Distribution Channel
      • 11.2.4.3. Qatar
      • 11.2.4.3.1. By Type of Infection
      • 11.2.4.3.2. By Route of Administration
      • 11.2.4.3.3. By Distribution Channel
      • 11.2.4.4. Kuwait
      • 11.2.4.4.1. By Type of Infection
      • 11.2.4.4.2. By Route of Administration
      • 11.2.4.4.3. By Distribution Channel
      • 11.2.4.5. South Africa
      • 11.2.4.5.1. By Type of Infection
      • 11.2.4.5.2. By Route of Administration
      • 11.2.4.5.3. By Distribution Channel
      • 11.2.4.6. Nigeria
      • 11.2.4.6.1. By Type of Infection
      • 11.2.4.6.2. By Route of Administration
      • 11.2.4.6.3. By Distribution Channel
      • 11.2.4.7. Algeria
      • 11.2.4.7.1. By Type of Infection
      • 11.2.4.7.2. By Route of Administration
      • 11.2.4.7.3. By Distribution Channel
      • 11.2.4.8. Rest of MEA
      • 11.2.4.8.1. By Type of Infection
      • 11.2.4.8.2. By Route of Administration
      • 11.2.4.8.3. By Distribution Channel

12. Competitive Landscape

  • 12.1. List of Key Players and Their Offerings
  • 12.2. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Company Market Share Analysis, 2023
  • 12.3. Competitive Benchmarking, By Operating Parameters
  • 12.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

13. Impact of Escalating Geopolitical Tensions on Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

14. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 14.1. Pfizer
  • 14.2. Merck & Co.
  • 14.3. AbbVie
  • 14.4. F. Hoffmann-La Roche Ltd
  • 14.5. GlaxoSmithKline
  • 14.6. Johnson & Johnson
  • 14.7. Eli Lilly and Company
  • 14.8. Novartis AG
  • 14.9. Sanofi S.A.
  • 14.10. AstraZeneca PLC
  • 14.11. Teva Pharmaceutical Industries Ltd
  • 14.12. Mylan N.V.
  • 14.13. Other Prominent Players

15. Key Strategic Recommendations

16. Research Methodology

  • 16.1. Qualitative Research
    • 16.1.1. Primary & Secondary Research
  • 16.2. Quantitative Research
  • 16.3. Market Breakdown & Data Triangulation
    • 16.3.1. Secondary Research
    • 16.3.2. Primary Research
  • 16.4. Breakdown of Primary Research Respondents, By Region
  • 16.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable